Qudexy XR to help prevent migraine in kids ages 6 to 11
Part of Brain & nervous system clinical trials.
This study tests whether Qudexy XR can reduce migraine headaches in children ages 6 to 11. It looks for kids who are having frequent, disruptive migraine attacks and checks safety with careful medication rules.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is 6 to 11 years old at screening
- Your child weighs at least 17 kg but less than 50 kg
- Your child has had migraine-type headaches for at least 6 months
- Your child has headaches on at least 8 days in the last 28 days
- Your child’s headaches affect daily life (PedMIDAS score over 10, but less than 140)
- Your child is not having nonstop migraines for 28 days
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at ways to help children and teens with migraine headaches by testing a care approach that includes access to evidence-based treatment. It may help if your child has frequent migraine headaches and is starting (or not already on) certain migraine-preventive medicines.
This trial studies a mind-body balance approach to help reduce symptoms and disability from pediatric migraine. You may join if your child has migraine headaches and can follow study routines, including keeping a headache diary.
This trial studies a medicine for stopping a migraine attack in children and teens. It may help families understand which treatment works best during acute (during-attack) migraine pain.
This study follows kids and teens who already took part in an earlier migraine medication study to check long-term safety and comfort with oral ubrogepant tablets. It may help families understand whether this migraine tablet is safe to keep using over time.
This study tests whether an oral medicine called atogepant can reduce migraine activity in children ages 6–17 and checks its side effects. It’s meant for kids with episodic migraine (not the more constant types) who may benefit from preventive treatment.
This trial tests an oral medication called atogepant to see if it can prevent migraines in teens aged 12–17. It aims to reduce how often migraines happen and track any side effects.
Hear when a new Migraine Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.